Table 4.

The comparison between de novo group and non-de novo group.

	De novo (n = 7)	Non-de novo(n = 13)	p-valve
Age at onset (years)	4	13	0.021*
Gender (M:F)	5:2	7:6	0.642
CMTNS (median) (range)	12 (8–19)	11.5 (5–18)	0.692
CMTNS-G (median) (range)	1.36 (0.86–4)	1.24 (0.28–2.5)	0.371
Median CMAP (mean ± SE)	5.14 ± 1.33	6.90 ± 1.20	0.304
Median MCV (mean ± SE)	55.63 ± 4.42	59.16 ± 2.10	0.604
Ulnar CMAP (mean ± SE)	4.39 ± 2.72	4.37 ± 0.84	0.909
Ulnar MCV (mean ± SE)	49.80 ± 6.30	56.41 ± 1.88	0.400
Median SNAP (mean ± SE)	5.00 ± 0.50	4.22 ± 0.86	0.436
Median SCV (mean ± SE)	46.30 ± 5.20	49.98 ± 1.44	0.582

^*The values have significant difference (p < 0.05). CMTNS, Charcot–Marie–Tooth disease Neuropathy Scores; CMTNS-G, Charcot–Marie–Tooth disease neuropathy scores gradient; CMAP, compound muscle action potential; SNAP, sensory nerve action potential; MCV, motor nerve conduction velocity; SCV, sensory nerve conduction velocity.